Introduction
Osteoarthritis (OA) is the most common disease aVecting synovial joints and is one of the most prevalent chronic conditions aVecting Western populations [11] . The disease is anatomically characterised by cartilage breakdown, osteophyte formation at the margins of the joint and low grade synovial inXammation.
Hyaluronic acid (HA) is the molecule responsible for synovial Xuid's rheological properties, enabling it to act as a lubricant or shock-absorber depending upon the forces exerted upon it [4, 17] . Osteoarthritic synovial Xuid is characterised by a decrease in high molecular weight (MW) HA molecules and a reduction in the concentration of HA. These changes reduce the elastoviscosity of the synovial Xuid and compromise its ability to protect the joint.
Viscosupplementation is a therapeutic concept based on the injection of exogenous HA, or its derivatives, into the osteoarthritic joint, with the aim of decreasing pain and improving function through the restoration of the synovial Xuid's rheological properties [4] . The therapy's analgesic eVect is thought to be achieved by multiple mechanisms including reducing pain-eliciting nerve activity by providing an elastoviscous protective barrier around the nociceptive aVerent Wbres in the intercellular matrix. Research suggests that the long-term symptomatic eVect of the therapy (which exceeds the residence time of the product in the joint) may be due to the restoration of normal, endogenous synthesis of high quality HA [3] .
There are now more than 20 commercial viscosupplement formulations available world-wide from diVerent manufacturers. The MW and residence time in the joint varies between products, and their recommended dosing regimens for the treatment of symptomatic knee OA range from 1 to 5 injections at weekly intervals [6] . The number of injections required to achieve eYcacy is inversely related to the MW of the preparation used and, consequently, to the residence time in the joint.
Controlled studies versus placebo have shown that hylan G-F 20, a cross-linked high MW derivative of HA, can decrease pain and improve joint mobility in patients suVering from knee OA [1, 10, 13, 18, 20, 26] . After 3 £ 2 mL intraarticular injections administered 1 week apart, peak eYcacy occurs between 8 and 12 weeks after the administration of the Wrst injection, and can last for up to 12 months [18] . This regimen was established as being clinically superior to a regimen of 2 £ 2 mL administered 2 weeks apart [20] .
The overall tolerability of the treatment is good with a low incidence of local adverse events (AE's) [15, 24] . This incidence appears to be slightly elevated, but remains low compared to other therapies, in repeat courses of treatment [19, 23] . In a recent retrospective trial of 1,489 knees treated with hylan G-F 20 [24] , local treatment-related and procedurerelated AE rates were reported as 4.2% of patients and 2.4% of injections. The most frequently reported AE's were joint eVusion, joint swelling, arthralgia, joint warmth and injection site erythema. Most AE's were mild to moderate. Nevertheless, there is an obvious medical justiWcation for decreasing the total number of injections in order to decrease the risk of severe adverse events such as septic arthritis, associated with any intra-articular procedure, and to improve patient compliance and convenience. There is also signiWcant economic beneWt to be gained from reducing the number of injections required to complete treatment as physician time, patient time, clinic overheads and medical disposable costs that could all reduced.
It was hypothesised that this objective could be achieved by increasing the volume of hylan G-F 20 injected. Injections of 4 or 6 mL into the knee joint have never been tested in clinical trials so there are no published data available regarding the risk of local AE's such as pain, swelling and eVusion, or regarding their potential frequency and/or intensity.
The primary objective of this pilot study was therefore to assess the safety and eYcacy proWles of new dosing regimens of hylan G-F 20 in patients with knee OA, using higher single dose volumes (4 and 6 mL) and reducing the number of injections (1 or 2) and to compare these results to the dosing regimen currently approved (3 £ 2 mL) [21] . The secondary objective was to assess the safety and eYcacy proWles of a second cycle of these new dosing regimens. The possible relationship between clinical eYcacy and total volume injected (6 mL currently, up to 12 mL in this study) was also examined.
Materials and methods
The study was a prospective, multi-centre, randomised, open, Wve-arm trial conducted in France and Germany. The protocol and patient informed consent form were reviewed and approved by the appropriate independent ethics committee (IEC) and complied with the requirements of the international conference on harmonisation (ICH). Patient's written, informed consent was required before enrolment in the study. Investigators complied with the Declaration of Helsinki, "Guidance for Good Clinical Practice" and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use when developing the patient informed consent documents.
Patients
The main inclusion criteria were: Male or female patient aged 40 years or older with an active lifestyle, consulting for OA pain in one knee and scoring ¸50 and ·80 mm on a 100 mm OA pain visual analogue scale (VAS) where 0 mm = no pain and 100 mm = worst possible pain; tibiofemoral OA (ACR criteria) [2] , Kellgren-Lawrence grade II or III [14] diagnosed by standard X-rays taken within 3 months prior to enrolment; no surgical intervention planned in the study knee in the next 6 months. If taking analgesics (except permitted doses of paracetamol ·3 g/day for rescue analgesia), NSAIDs or cyclooxygenase-2 inhibitors, patient were required to comply with a washout period of 1-3 weeks depending on the half-life of the medication.
The main exclusion criteria were: Patients with bilateral symptomatic knee OA or predominantly patello-femoral involvement of the study knee; knee OA Xare with obvious tense eVusion, diagnosed by clinical examination, at the study knee; clinical symptoms of meniscal instability or signiWcant valgus/varus that required corrective osteotomy; signiWcant ligamentous instability; any prior viscosupplementation therapy or history of sepsis in the study knee; systemic or intra-articular injection of corticosteroids in any joint within 3 months of enrolment; chondrocalcinosis and microcrystals-mediated arthritis, concomitant inXammatory or other rheumatologic, neurological or cardiovascular diseases which could aVect the evaluation of knee pain.
Methods
Patients meeting the inclusion and exclusion criteria were randomised to 1 of 5 groups:
Group 1 : 1 intra-articular injection of 6 mL hylan G-F 20 Group 2 : 1 intra-articular injection of 4 mL hylan G-F 20 Group 3 : 2 intra-articular injections of 4 mL hylan G-F 20 administered 2 weeks apart Group 4 : 3 intra-articular injections of 4 mL hylan G-F 20 administered 1 week apart Group 5 : 3 intra-articular injections of 2 mL hylan G-F 20 administered 1 week apart Intra-articular injections were performed under strict aseptic technique by a trained physician using a lateral, medial mid patellar or antero-medial injection route (according to the injector's preference) after aspiration of any synovial Xuid.
Patients were followed-up 7 days after each injection then at 3, 8, 16 and 24 weeks after the Wrst injection. Safety and eYcacy were assessed at each patient visit. At week 24, patients who scored ¸50 and ·80 mm on the pain VAS, or patients who experienced a worsening of pain (>15 mm on VAS) compared to week 16, were eligible to receive a second cycle of treatment (Extension Study). Patients undergoing a second cycle of treatment received the same dosing regimen as that dictated by their original randomisation.
Safety assessment
Target knee and systemic AE's were monitored throughout the study. Additionally, patients assessed overall safety using a four point side-eVect rating scale.
EYcacy assessment
The primary eYcacy endpoint was the patient-completed study knee OA pain score (VAS) 24 weeks after the Wrst injection, compared to baseline.
The secondary endpoints were the patient-completed study knee OA pain score (VAS) at all other time points; improvement in pain, stiVness and functional impairment as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC™) [5] , and patient and physician global assessment of OA in the target knee using a 100 mm VAS at all visits. Concomitant use of permitted rescue medication (paracetamol ·3 g/day) was also recorded.
Statistical methods
The
The primary eYcacy hypothesis was evaluated by the change from baseline to the week 24 evaluation in the patient's assessment of target knee OA pain during the previous 48 h on VAS. This endpoint was analysed for each treatment group in the ITT population (all patients who underwent the Wrst injection and had at least one post-baseline eYcacy assessment) using a paired t test. No statistical analysis was performed between treatment groups.
The secondary endpoints (patient-completed knee OA pain score on VAS at all other time points; total WOMAC score; WOMAC A (pain), B (stiVness), and C (physical function) sub-scores; patient global assessment (VAS) and physician global assessment (VAS)) were analysed similarly. The number and percentage of patients using paracetamol was tabulated for each treatment group at each visit. Paracetamol use was summarised by: number of patients, mean, median, standard deviation and range at each visit for each treatment group.
Results
The ITT population consisted of 100 patients (56 female and 44 male) with a mean age of 61.1 years (range 41-86 years). These and other demographic parameters were similarly distributed between the Wve treatment groups (Table 1) . Patient disposition, re-treatment rates and reasons for discontinuation are shown in Table 2 .
Safety
The treatment was well tolerated. There were no serious or severe, device-related AE's in any of the studied dosing regimens, nor were any new safety concerns identiWed following initial or repeat treatment. Group 4 (3 £ 4 mL) had the highest percentage of patients reporting device-related local AE's (30%) while Group 1 (1 £ 6 mL) and Group 5 (3 £ 2 mL) had only 10% (Table 3) . These device-related local AE's consisted mostly of mild or moderate postinjection pain (n = 12 patients) with local inXammation (described as synovitis by some investigators, n = 3) or eVusion (n = 1). Post-hoc analyses using Fisher's Exact Test which compared incidence of target knee treatmentemergent AEs between groups 1-4 compared with Group 5 did not show any statistically signiWcant diVerences between groups.
Twenty-four patients (24%) were re-treated in the extension study (Table 2) . No safety concerns were raised by retreatment with the same injection schedules. Four patients that were re-treated experienced Wve target knee AE's (Table 3) . No patients experienced AE's in Group 1, while one patient reported an AE in each of Groups 2-5. None of the target knee, treatment-emergent AE's was serious. One patient in Group 4 (3 £ 4 mL) discontinued from the study due to synovitis with eVusion at the target knee. One case of synovitis in Group 5 (3 £ 2 mL) was severe.
EYcacy
Treatment with hylan G-F 20 resulted in a statistically signiWcant improvement from baseline to week 24 in all endpoints for all treatment regimens (Fig. 1) . The largest changes were observed in Group 5 (3 £ 2 mL) with a mean change [SD] from baseline at week 24 in the patient-completed knee OA pain VAS score of ¡36.7 mm [26.9] . Groups 1 (1 £ 6 mL) and 4 (3 £ 4 mL) consistently showed similar mean improvement (respectively ¡34.9 mm [16.4] and ¡32.6 mm [25.3] ). Smaller changes (¡24.0 mm [22.9] and ¡24.3 mm [28.3]) were found in Group 3 (2 £ 4 mL) and Group 2 (1 £ 4 mL). Table 4 summarises the rankings of mean response to treatment for all primary and secondary endpoints by treatment group. When the results of all assessment criteria were added together, Group 4 (3 £ 4 mL) was ranked Wrst. Group 1 (1 £ 6 mL) was ranked second and was either Wrst or second in 5 of the 6 endpoints.
Twenty-four patients (those who had a VAS pain scorȩ 50 and ·80 mm at week 24, or those who had a 15 mm increase in pain between weeks 16 and 24) were re-treated in the extension study. The group with the highest number of re-treated patients (n = 7) was Group 3 (2 £ 4 mL). Group 1 (1 £ 6 mL) had the lowest number of patients qualifying for repeat treatment (Table 2) .
Discussion
The principal objective of this pilot study was to examine the safety of alternate dosing regimens of hylan G-F 20 to that currently approved for the treatment of symptomatic knee OA (3 £ 2 mL). Though this study was not powered to demonstrate statistical diVerence on eYcacy analysis, trends in eYcacy data were examined using patient-completed questionnaires and physician assessments to provide insight into possible alternate dosage regimens with higher volumes and lower numbers of injections. Another objective was to examine the safety of giving a second course of these alternate dosing regimens. The data presented here suggest that alternative protocols could be proposed to replace the current 3 £ 2 mL regimen of viscosupplementation with hylan G-F 20, oVering similar clinical eYcacy without a greater percentage of adverse events. In patients with hip [7, 8, 22] , shoulder [12] and ankle [25] OA, experience with a single intra-articular injection of 2 mL hylan G-F 20 has demonstrated signiWcant immediate, and sustained, symptomatic eVect for up to 6 months.
Among the hypotheses explaining these eYcacy eVects is the suggestion that these joints have a smaller volume than the knee and consequently a single injection of 2 mL hylan G-F 20 would exhibit a greater 'Wll' ratio. Increasing the 'Wll' in the knee by injecting a single dose of a higher volume (6 mL as opposed to 2 mL currently) could therefore be likely to provide improved immediate and sustained eYcacy.
Given the known safety proWle of hylan G-F 20 in its current usage [9, 16] and the volume of the knee space, it was thought that the injection of the proposed volumes should not pose major safety concerns. This has been conWrmed by the present data which show no more target knee AE's in the 1 £ 6 mL group than in the 3 £ 2 mL group. The percentage of device-and procedure-related AE's (all mild or moderate in intensity) in these two groups was similar to that previously published in clinical trials using a 3 £ 2 mL dosing regimen. In contrast, the 3 £ 4 mL group experienced about three times more local AE's than expected [15, 24] . Nevertheless none of these AE's was serious and no severe, acute, inXammatory reactions were reported.
In summary, the risk/beneWt proWle of a single 6 mL injection appears to be good and this regimen could be developed as an alternative to the currently approved 3 £ 2 mL regimen for the treatment of symptomatic knee OA. There is indeed a medical need to have eVective and safe single injection products since repeated intra-articular injections can be a limiting factor for viscosupplementation treatment. A 6 mL single injection could be particularly useful for patients undergoing concomitant anti-thrombotic therapy (i.e. vitamin K antagonists, aspirin, clopidogrel). In those patients with active and busy lifestyles, or who have travelling challenges due to distance or schedule, a single dose treatment regimen may improve patient compliance. Additionally, a single dose regimen would reduce the risk of procedure-related local AE's, particularly infectious arthritis and oVer medico-economic beneWts. Furthermore, not only a single injection allows a major compliance from the patients and reduces risks connected to intra-articular injection, but also has its importance in pharmaco-economics: a minor number of injections shortens medical costs connected to hospital visits, medications, work time of physicians and nurses and patients absenteeism.
These data support the need for a large-scale, prospective clinical trial comparing the safety and eYcacy of a single 6 mL intra-articular injection of hylan G-F 20 to placebo, in patients suVering from knee osteoarthritis.
